Iovance Biotherapeutics (IOVA) Inventory Average (2023 - 2026)

Iovance Biotherapeutics (IOVA) has reported Inventory Average for 4 consecutive years, with $55.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory Average fell 5.99% year-over-year to $55.0 million; the TTM figure through Mar 2026 stood at $55.0 million (down 5.99% YoY), while the FY2025 annual figure was $51.6 million, up 66.74% from the prior year.
• Inventory Average grew to $55.0 million in Q1 2026 per IOVA's latest filing, from $51.7 million in the prior quarter.
• Across five years, Inventory Average topped out at $58.5 million in Q1 2025 and bottomed at $9.5 million in Q3 2023.
• Historically, Inventory Average has averaged $38.4 million across 4 years, with a median of $51.2 million in 2025.
• Annual changes were most pronounced in 2025 — Inventory Average surged 318.25% — and 2026, when it fell 5.99%.
• Iovance Biotherapeutics' Inventory Average stood at $9.8 million in 2023, then soared by 43.04% to $14.0 million in 2024, then soared by 269.39% to $51.7 million in 2025, then gained by 6.45% to $55.0 million in 2026.
• Business Quant data shows IOVA's Inventory Average at $55.0 million in Q1 2026, $51.7 million in Q4 2025, and $50.8 million in Q3 2025.